Clinical trial Recruiting at 1 site Observational Ages 18 and up

New ways to measure heart changes in sleep apnea

Official title: Prospective Evaluation of New Metrics to Assess Cardiovascular Remodeling in Obstructive Sleep Apnea

Run by University Hospital, Antwerp · NCT07427589 · Data updated 2026-11-12

This study tests whether beyond-the-ordinary sleep apnea metrics can reveal cardiovascular changes and compares CPAP, MADs, and hypoglossal nerve stimulation in adults with OSA.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment270 (estimated)
SponsorUniversity Hospital, Antwerp
Academic / other
Locations1 site (Antwerp)
StatusRecruiting
StartedJune 10, 2026
Main results expectedDecember 2029
Study endsDecember 2029
Registry record updatedJune 29, 2026
Trial IDNCT07427589 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) with AHI ≥15 who are Dutch-speaking and eligible for CPAP, MAD, or hypoglossal nerve stimulation at Antwerp University Hospital.

Probably not a fit

Patients with severe cardiomyopathy, significant valvular disease, congenital heart disease, or recent effective CPAP use may see limited benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective observational study aims to characterize endophenotypes of obstructive sleep apnea and associated cardiovascular remodeling using novel metrics such as hypoxic burden, sleep-related heart rate responses, and PWADs. It will examine how these metrics relate to cardiovascular changes and how different therapies (CPAP, MADs, and hypoglossal nerve stimulation) affect cardiovascular parameters. Participants are adults with AHI ≥15, Dutch-speaking, and eligible for their therapy, recruited at Antwerp University Hospital. Central exclusions include significant cardiometabolic disease and prior related therapies that could confound results. The study seeks to broaden understanding beyond traditional AHI-based assessments in OSA.

Why it matters

Potential benefit: If successful, the study could improve understanding of how different OSA treatments influence cardiovascular risk.

How similar studies have gone: Previous work in OSA has shown cardiovascular implications, though this specific endophenotype-focused approach is still investigational.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* AHI ≥ 15 events/hour, based on a recent (\<2 years) PSG, conducted in Antwerp University Hospital
* Patients must be 18 years or older
* Patients must be dutch-speaking
* Patients must be eligible for their therapy (CPAP, MAD or HNS)
* Willing to participate after informed consent

Exclusion Criteria:

* Central apneas accounting for ≥25% of total apneas during baseline polysomnography
* Patients who have received effective CPAP therapy (defined as CPAP use for ≥4 h/night) within the previous 6 months
* Patients with prior MAD therapy
* Uncontrolled hypertension
* Known cardiomyopathy
* Significant coronary arterial disease
* Clinically significant valvular heart disease, defined as more than mild left-sided valvular disease or more than moderate right-sided valvular disease
* Congenital heart disease
* Participants may be excluded if, after rescoring, outcome measures do not meet predefined criteria

Where it's running

  • Antwerp University Hospital
    Antwerp, Belgium
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.